Sign in
VYNE Stock Price, Chart, Stats & News
VYNE Therapeutics Inc.
Save
VYNE Therapeutics Inc. (VYNE) does not currently pay a dividend.
14.88M
Market cap
–
Current P/E
–
Forward P/E
VYNE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.12% |
Operating margin | -5219.12% |
Pretax margin | -4689.82% |
Net margin | -4646.14% |
Effective tax rate | -0.01% |
ROA | -87.81% |
ROE | -74.15% |
D/E | – |
Interest coverage ratio | – |
VYNE valuation
P/E | – |
P/S | 17.28x |
P/B | 0.91x |
P/CF | -0.76x |
P/FCF | -0.30x |
P/OCF | -0.76x |
PEG | -0.05x |
EV multiple | -1.15x |
About
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis.
Similar securities
Based on sector and market capitalization
Report issue